Anti-CD99 monoclonal antibody
Cancer
Discovery/Pre-clinicalProprietary antibody identified
Key Facts
Indication
Cancer
Phase
Discovery/Pre-clinical
Status
Proprietary antibody identified
Company
About Caedo Oncology
Caedo Oncology is an early-stage biotech focused on creating improved cancer treatments through unique immunotherapy approaches that trigger novel, caspase-independent programmed cell death pathways. Founded in 2020 based on research from Oslo University Hospital, the company's proprietary antibodies target cell surface proteins like CD47, CD99, and HLA class I molecules. Its main shareholder is the venture capital fund Sarsia Seed, and it has secured a significant grant from the Norwegian Research Council. The company is led by a team with deep experience in immunology, antibody engineering, and biotech commercialization.
View full company profileTherapeutic Areas
Other Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Not Specified (Oncology Focus) | Narwhal Bio | Pre-clinical |
| EDM Platform for Genetic Medicine | Coastar Therapeutics | Pre-clinical |
| CO-1 | Caedo Oncology | Pre-clinical |
| Anti-HLA class I monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Triapine® | Nanopharmaceutics | Clinical |
| Ammonium Tetrathiomolybdate | Nanopharmaceutics | Clinical |
| Aza-TdC | Nanopharmaceutics | Clinical |
| Undisclosed Oncology Program(s) | Cell BioEngines | Phase 1 |
| No-alpha IL-2 Mutein | SarcoMed USA | Pre-clinical |
| PMIS Therapeutic | NaturemiRI | Preclinical/Clinical (unspecified) |
| AUM302 (formerly IBL-302) | Inflection Biosciences | Pre-clinical (partnered) |
| Undisclosed DDR Sensor Program(s) | NERx Biosciences | Pre-clinical |